Redmond biotech company Cerevast Therapeutics has raised $10 million as it continues to test a headset it hopes will one day be used to treat stroke patients. That brings the company’s total fundraising up to nearly $32.5 million, according to company CEO Bradford Zakes. The company was formed in 2009 and announced earlier this year it had passed its first interim safety analysis as it rolls out trials of its “Clotburst ER” device.
Cerevast Therapeutics, a 5-year-old Redmond company that’s developing a novel approach for treating stroke patients with ultrasound, has raised $10 million in fresh funding, according to a filing with the SEC. Led by Bradford Zakes, Cerevast was formed in 2009 after the company purchased the assets of ImaRx Therapeutics. Zakes previously worked at ICOS and Glaxo. Earlier this year, the company said that its device passed four independent safety reviews, and that it continued to move forward with clinical studies. Here’s how the company describes the ClotBuster device, which attaches to a patient’s head.
NOTE: TECHi Two-Takes are the stories we have chosen from the web along with a little bit of our opinion in a paragraph. Please check the original story in the Source Button below.
TECHi weighs both sides before reaching a conclusion.
TECHi’s editorial take above outlines the reasoning that supports this position.
For the past six years, an early-stage startup accelerator known as The Founder Institute has been conducting research on the differences between…
In less than three years, Tinder has managed to claw its way to the top of the already crowded dating…
With how ridiculously popular ride-sharing services like Uber, companies in several other fields have been looking to achieve a similar…
Expedia has been on an acquisition spree recently and has consolidated the OTA market to the point where there's now…
